An intervention to stop tobacco use among patients suspected of tuberculosis (TB)

An intervention to stop tobacco use among patients suspected of tuberculosis (TB): an evaluation of an integrated approach

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN08829879

Enrollment

1100

Registered

2009-03-17

Start date

2008-12-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis and tobacco use Infections and Infestations Respiratory tuberculosis, not confirmed bacteriologically or histologically

Interventions

A total of 22 primary care health centres will be selected (11 each for control and intervention arms) and 50 patients recruited with suspected tuberculosis in each of these centres. In the interven

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In each health centre, we will approach adult patients (greater than or equal to 18 years, either sex), who cough for three or more weeks and are therefore suspected and screened for pulmonary tuberculosis.

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
1. Point abstinence at 4 weeks: the proportion of trial participants who have completely given up all forms of nicotine use at four weeks after the completion of NRT, bupropion and/or brief counselling therapy 2. Continuous abstinence up to 6 months: proportion of trial participants who remained abstinent from 4 weeks onwards up to six months 3. We will also measure tobacco use, e.g. number of cigarettes smoked per day to estimate any reduction in tobacco use secondary to the intervention	—

Measure

Time frame

1. Point abstinence at 4 weeks: the proportion of trial participants who have completely given up all forms of nicotine use at four weeks after the completion of NRT, bupropion and/or brief counselling therapy 2. Continuous abstinence up to 6 months: proportion of trial participants who remained abstinent from 4 weeks onwards up to six months 3. We will also measure tobacco use, e.g. number of cigarettes smoked per day to estimate any reduction in tobacco use secondary to the intervention

—

Secondary

Measure	Time frame
1. Incidence of various adverse affects secondary to therapy 2. Economic outcomes assessed in terms of healthcare cost to get one person to stop smoking at four weeks. Healthcare cost will include the treatment cost, the average duration of health professionals' time spent with the patients during assessment, advice and counselling. 3. Process outcomes include: 3.1. The proportion of tobacco users who decide to quit and registered to receive 'five steps to quit' intervention 3.2. The proportion of people registered who continue follow-up for the full period planned	—

Measure

Time frame

1. Incidence of various adverse affects secondary to therapy 2. Economic outcomes assessed in terms of healthcare cost to get one person to stop smoking at four weeks. Healthcare cost will include the treatment cost, the average duration of health professionals' time spent with the patients during assessment, advice and counselling. 3. Process outcomes include: 3.1. The proportion of tobacco users who decide to quit and registered to receive 'five steps to quit' intervention 3.2. The proportion of people registered who continue follow-up for the full period planned

—

Countries

Pakistan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 1, 2026